Join the 'Immune Globulin Intravenous' group to help and get support from people like you.
Immune Globulin Intravenous News
CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults
Posted 21 Sep 2017 by Drugs.com
KING OF PRUSSIA, Pa. — 14 September 2017 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability. CIDP is a rare autoimmune disorder that affects t ...
Posted 13 Mar 2017 by Drugs.com
MONDAY, March 13, 2017 – Lab experiments with monkeys suggest that "immunotherapy" holds promise as a long-term treatment for HIV, researchers say. Treatment with two anti-HIV antibodies right after infection might help keep the AIDS-causing virus in check for a prolonged period, according to the new study. Despite an arsenal of HIV drugs, effective long-term treatment remains elusive because ...
Posted 21 Feb 2017 by Drugs.com
-- If you have allergies, regular shots (immunotherapy) are designed to make you less sensitive to allergens over time. The American Academy of Allergy, Asthma and Immunology says you may be a candidate for allergy shots if: Your symptoms are moderate-to-severe and your allergy season lasts a few months or more. You want to avoid long-term use of allergy medications. You can commit the time ...
Posted 29 Dec 2012 by Drugs.com
DREIEICH, Germany and BOCA RATON, Fla., Dec. 20, 2012 /PRNewswire/ – Biotest AG announced today that Biotest Pharmaceuticals Corporation received approval for Bivigam for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food and Drug Administration (FDA). Bivigam is the first polyspecific intravenous immune globulin manufactured in the U.S. by Biotest ...
Posted 27 Jul 2011 by Drugs.com
WEDNESDAY, July 27 – A combination therapy that "desensitizes" kidney transplant recipients could help hard-to-match patients find a needed kidney faster. The desensitization procedure combines the use of plasmapheresis – a machine that filters the blood plasma to remove antibodies – and low-doses of a medication called intravenous immune globulin (IVIG). The combination of these therapies ...
Posted 20 Apr 2010 by Drugs.com
KING OF PRUSSIA, Pa., April 19 /PRNewswire/ – CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life for Privigen, Immune Globulin Intravenous (Human), 10% Liquid, from 24 to 36 months. The approval makes Privigen the first liquid intravenous immunoglobulin (IVIg) in the U.S. that can ...
Ask a Question
Related Condition Support Groups
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Primary Immunodeficiency Syndrome, Autoimmune Neutropenia, Idiopathic (Immune) Thrombocytopenic Purpura, Bone Marrow Transplantation, Chronic Lymphocytic Leukemia (CLL), Evan's Syndrome, Anti NMDA Receptor Encephalitis, HIV Infection, Kawasaki Disease, Myasthenia Gravis, Polymyositis / Dermatomyositis
Related Drug Support Groups
Gamunex, Privigen, Carimune, Octagam, Panglobulin, Panglobulin NF, Gammar IV, Gamimune, Gamimune N 10%, view more... Gamimune N 5%, Gammagard S / D, Gammar-P IV, Flebogamma, Bivigam, Venoglobulin-S 10%, Venoglobulin-S 5%, Carimune NF, Sandoglobulin, Gammaplex, Polygam S / D, Iveegam En